Figure 1
Figure 1. Modulation of PVR, MICA, and MICB expression on the SKO-007(J3) cell line after doxorubicin or melphalan treatment. (A) PVR, MICA, and MICB surface expression was analyzed by flow cytometry on SKO-007(J3) cells treated with doxorubicin (0.05 μM) or melphalan (22 μM) for 48 hours. The gray histogram represents the isotype control antibody, whereas dashed lines represent the specific ligand. Data are representative of 1 of 4 independent experiments. (B) The corresponding increase in mRNA levels has been tested after 24 hours by real-time PCR performed as described in “Real-time PCR.” Data, expressed as arbitrary units, were normalized with β-actin, and referred to untreated cells considered as calibrator. Data are from the same experiment shown in panel A and are presented as the means plus or minus SD of triplicates. Significant differences as calculated by paired Student t test are indicated: *P < .01; **P < .05.

Modulation of PVR, MICA, and MICB expression on the SKO-007(J3) cell line after doxorubicin or melphalan treatment. (A) PVR, MICA, and MICB surface expression was analyzed by flow cytometry on SKO-007(J3) cells treated with doxorubicin (0.05 μM) or melphalan (22 μM) for 48 hours. The gray histogram represents the isotype control antibody, whereas dashed lines represent the specific ligand. Data are representative of 1 of 4 independent experiments. (B) The corresponding increase in mRNA levels has been tested after 24 hours by real-time PCR performed as described in “Real-time PCR.” Data, expressed as arbitrary units, were normalized with β-actin, and referred to untreated cells considered as calibrator. Data are from the same experiment shown in panel A and are presented as the means plus or minus SD of triplicates. Significant differences as calculated by paired Student t test are indicated: *P < .01; **P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal